Alphatec Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alphatec Holdings, Inc. on November 6, 2012. The report details the closing of a strategic asset purchase transaction with Phygen, LLC, aimed at expanding the Company's portfolio of spinal implant products and intellectual property.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels for a reporting period. Instead, it outlines the specific consideration paid for the asset acquisition:
- Cash Consideration: $2 million paid to Phygen, LLC.
- Stock Consideration (Issued): 4,069,087 unregistered shares of common stock.
- Stock Consideration (Escrow): 1,170,960 unregistered shares held in escrow to secure indemnification obligations for 12 months.
- Total Shares Issued: 5,240,047 shares.
Material Changes
The primary material change is the acquisition of assets related to the design, development, marketing, and distribution of spinal implant products, including associated intellectual property, contractual rights, inventories, and certain liabilities. Additionally, the Company secured an exclusive, worldwide license for Phygen's proprietary Autolok set screw locking technology.
Outlook, Risks, and Unusual Items
Lock-Up Restrictions: Phygen is subject to lock-up restrictions on the shares received. These restrictions lapse in three tranches on the first, second, and third annual anniversaries of the closing (1,922,049 shares, 1,658,999 shares, and 1,658,999 shares, respectively).
Regulatory Status: All shares were issued in reliance on exemptions from registration under Section 4(2) of the Securities Act of 1933 and/or Rule 506 of Regulation D.
Documentation: Full details of the Asset Purchase Agreement and Autolok License Agreement are expected to be filed as exhibits to the Company's Annual Report on Form 10-K for the period ending December 31, 2012.
Key Facts for Investor Verification
- Verify the exact valuation of the acquired assets and liabilities in the full Asset Purchase Agreement.
- Confirm the impact of the 5,240,047 new shares on existing shareholder dilution.
- Review the specific indemnification obligations secured by the escrowed shares.
- Assess the commercial potential and patent status of the Autolok set screw locking technology.
- Monitor the future filing of the definitive agreements in the 2012 Form 10-K.